TSCAN THERAPEUTICS, INC. Revenue
TSCAN THERAPEUTICS, INC. (TCRX) reported Revenue of $1.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-12
- TSCAN THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $1.05M, a 65.83% decline year-over-year.
- TSCAN THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $982.00K, a 54.77% decline year-over-year.
- TSCAN THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $2.57M, a 286.02% increase year-over-year.
- TSCAN THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $2.51M, a 139.37% increase year-over-year.
- TSCAN THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $10.32M, a 266.65% increase from fiscal 2024.
- TSCAN THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $2.82M, a 86.62% decline from fiscal 2023.
- TSCAN THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $21.05M, a 55.52% increase from fiscal 2022.
- TSCAN THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $13.54M, a 33.47% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.05M 10-Q · filed 2026-08-12 | $2.03M 10-Q · filed 2026-08-12 | $4.60M derived: sum of 3 quarters · filed 2026-08-12 | $7.11M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $982.00K 10-Q · filed 2026-05-06 | $3.55M derived: sum of 2 quarters · filed 2026-05-06 | $6.06M derived: sum of 3 quarters · filed 2026-05-06 | $9.14M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $5.08M derived: sum of 2 quarters · filed 2026-03-04 | $8.15M derived: sum of 3 quarters · filed 2026-08-12 | $10.32M 10-K · filed 2026-03-04 |
| 2025-09-30 | $2.51M 10-Q · filed 2025-11-12 | $5.59M derived: sum of 2 quarters · filed 2026-08-12 | $7.76M 10-Q · filed 2025-11-12 | $8.42M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $3.08M 10-Q · filed 2026-08-12 | $5.25M 10-Q · filed 2026-08-12 | $5.91M derived: sum of 3 quarters · filed 2026-08-12 | $6.96M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.17M 10-Q · filed 2026-05-06 | $2.84M derived: sum of 2 quarters · filed 2026-05-06 | $3.88M derived: sum of 3 quarters · filed 2026-05-06 | $4.42M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $665.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $1.71M derived: sum of 2 quarters · filed 2026-03-04 | $2.25M derived: sum of 3 quarters · filed 2026-03-04 | $2.82M 10-K · filed 2026-03-04 |
| 2024-09-30 | $1.05M 10-Q · filed 2025-11-12 | $1.58M derived: sum of 2 quarters · filed 2025-11-12 | $2.15M 10-Q · filed 2025-11-12 | $9.36M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $536.00K 10-Q · filed 2025-08-12 | $1.10M 10-Q · filed 2025-08-12 | $8.31M derived: sum of 3 quarters · filed 2025-08-12 | $12.20M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $566.00K 10-Q · filed 2025-05-06 | $7.78M derived: sum of 2 quarters · filed 2025-05-06 | $11.66M derived: sum of 3 quarters · filed 2025-05-06 | $14.81M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $7.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $11.10M derived: sum of 2 quarters · filed 2025-03-05 | $14.25M derived: sum of 3 quarters · filed 2025-03-05 | $21.05M 10-K · filed 2025-03-05 |
| 2023-09-30 | $3.89M 10-Q · filed 2024-11-12 | $7.04M derived: sum of 2 quarters · filed 2024-11-12 | $13.84M 10-Q · filed 2024-11-12 | $16.93M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $3.15M 10-Q · filed 2024-08-12 | $9.95M 10-Q · filed 2024-08-12 | $13.05M derived: sum of 3 quarters · filed 2024-08-12 | $16.41M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $6.80M 10-Q · filed 2024-05-13 | $9.90M derived: sum of 2 quarters · filed 2024-05-13 | $13.26M derived: sum of 3 quarters · filed 2024-05-13 | $17.32M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $6.46M derived: sum of 2 quarters · filed 2024-03-06 | $10.51M derived: sum of 3 quarters · filed 2024-03-06 | $13.54M 10-K · filed 2024-03-06 |
| 2022-09-30 | $3.36M 10-Q · filed 2023-11-09 | $7.42M derived: sum of 2 quarters · filed 2023-11-09 | $10.44M 10-Q · filed 2023-11-09 | $13.29M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $4.06M 10-Q · filed 2023-08-10 | $7.08M 10-Q · filed 2023-08-10 | $9.93M derived: sum of 3 quarters · filed 2023-08-10 | $12.34M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $3.02M 10-Q · filed 2023-05-10 | $5.88M derived: sum of 2 quarters · filed 2023-05-10 | $8.29M derived: sum of 3 quarters · filed 2023-05-10 | $11.13M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $5.27M derived: sum of 2 quarters · filed 2023-03-08 | $8.11M derived: sum of 3 quarters · filed 2023-03-08 | $10.14M 10-K · filed 2023-03-08 |
| 2021-09-30 | $2.41M 10-Q · filed 2022-11-09 | $5.26M derived: sum of 2 quarters · filed 2022-11-09 | $7.29M 10-Q · filed 2022-11-09 | $8.08M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $2.85M 10-Q · filed 2022-08-10 | $4.88M 10-Q · filed 2022-08-10 | $5.67M derived: sum of 3 quarters · filed 2022-08-10 | $5.96M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $2.03M 10-Q · filed 2022-05-12 | $2.82M derived: sum of 2 quarters · filed 2022-05-12 | $3.11M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $795.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $1.08M derived: sum of 2 quarters · filed 2022-03-09 | $1.08M 10-K · filed 2022-03-09 | |
| 2020-09-30 | $290.00K 10-Q · filed 2021-11-10 | $290.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |